Novel Treatment Options for Multiple Myeloma.

Area of Science:

• Hematologic Oncology
• Immunotherapy
• Precision Medicine

Background:

• Multiple myeloma (MM) is a prevalent hematologic malignancy characterized by treatment resistance and relapse.
• Despite its incurable nature, recent breakthroughs are revolutionizing MM care paradigms.

Purpose of the Study:

• To review the evolving treatment strategies for multiple myeloma (MM) from diagnosis to relapsed/refractory disease.
• To highlight the impact of novel immunotherapies, targeted therapies, and future investigational agents.

Main Methods:

• Literature review of recent therapeutic advancements in multiple myeloma.
• Analysis of shifting treatment paradigms in frontline and relapsed/refractory settings.
• Exploration of precision medicine approaches and emerging therapies.

Main Results:

• Frontline MM treatment now considers suitability for quadruplet therapy beyond transplant eligibility.
• Novel immunotherapies like CAR-T cells and bispecific antibodies offer new hope for relapsed/refractory MM.
• Targeted therapy with venetoclax shows efficacy in the t(11;14) translocation subgroup.

Conclusions:

• Emerging therapies like investigational CAR-T, cereblon E3 ligase modulators, and antibody-drug conjugates promise improved responses.
• Challenges include managing toxicity, ensuring access, and optimizing treatment sequencing for personalized care.
• Balancing treatment efficacy with quality of life is crucial as the therapeutic landscape expands.